Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences

Brütting, Julia; Bergmann, Max; Schadendorf, Dirk; Weber, Christiane; Tilgen, Wolfgang; Berking, Carola; Meier, Friedegund; Nvkh,

doi:10.1111/ddg.13831

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, they fully depended on the physician's form of presentation. With 91 % booklets are the most used source of information distributed by dermatologist [19]. Although our psychological handling with patients in general was evaluated as "good", a few patients expressed the need for a more extensive psychological care.…”

Section: Discussionmentioning

confidence: 99%

Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies

Reschke

Jäger

Mehnert‐Theuerkauf

et al. 2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Objective Our aims were to investigate the motivation for therapy, the understanding and valuation of potential treatment toxicities in melanoma patients offered adjuvant therapies. Methods Between September 2018 and September 2019 49 adjuvant patients with stage III and IV melanoma received a self‐created, pre‐treatment questionnaire. Furthermore, the patients were handed out the REPERES‐G, EQ‐5D‐3L and EORTC QLQ C‐30 questionnaires. Results Eight patients (18.3 %) decided against adjuvant therapy (mean age 71.6 years). Four of these had stage IIIA melanoma. The majority of patients (73.4 %) decided for adjuvant treatment with PD1‐inhibitors despite their potential high grade, persistent, irreversible or even fatal toxicities. About a third of patients with BRAF V600 mutated melanoma who decided for therapy chose targeted therapy (31.3 %). These patients were younger (mean age 49 years), still working and had families with children. The REPERES‐G questionnaire showed that our patients were generally satisfied with medical care. The average scores in the EQ‐5D‐3L and EORTC QLQ C‐30 questionnaires indicated good subjective general health. Conclusions Despite the associated toxicities as well as the required time and effort for a one‐year treatment the majority of patients decided for adjuvant treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies

Reschke

Jäger

Mehnert‐Theuerkauf

et al. 2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Sie verließen sich demnach vollständig auf die Informationen ihres Arztes beziehungsweise ihrer Ärztin. Mit 91 % sind Broschüren die am häufigsten von Dermatologen verteilten Informationsquellen [19]. Obwohl unser psychologischer Umgang mit Patienten im Allgemeinen als „gut“ bewertet wurde, äußerten einige Patienten die Notwendigkeit einer umfassenderen psychologischen Betreuung.…”

Section: Diskussionunclassified

Therapieverständnis und gesundheitsbezogene Lebensqualität bei Patienten mit Melanom im Stadium III/IV unter Behandlung mit neuen adjuvanten Therapien

Reschke

Jäger

Mehnert‐Theuerkauf

et al. 2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Ziel Unser Ziel war es, die Therapiemotivation, das Verständnis und die Abschätzung potenzieller Toxizität der Behandlung bei Melanompatienten, denen eine adjuvante Therapie vorgeschlagen wurde, zu untersuchen. Methoden Zwischen September 2018 und September 2019 beantworteten 49 Patienten mit Melanom im Stadium III oder IV vor der möglichen adjuvanten Behandlung einen selbst erstellten Fragebogen. Darüber hinaus wurden den Patienten die Fragebögen REPERES‐G, EQ‐5D‐3L und EORTC QLQ C‐30 vorgelegt. Ergebnisse Acht Patienten (18,3 %) entschieden sich gegen eine adjuvante Therapie (Durchschnittsalter 71,6 Jahre). Vier davon hatten ein Melanom im Stadium IIIA. Die meisten Patienten (73,4 %) entschieden sich trotz der potenziell hochgradigen, persistierenden, irreversiblen oder sogar tödlichen Toxizität für eine adjuvante Behandlung mit PD1‐Inhibitoren. Etwa ein Drittel der Patienten mit einem Melanom mit BRAF V600‐Mutation, die sich für eine Therapie entschieden hatten, wählten eine zielgerichtete Therapie (31,3 %). Diese Patienten waren jünger (Durchschnittsalter 49 Jahre), noch berufstätig und hatten Familien mit Kindern. Der REPERES‐G‐Fragebogen ergab, dass unsere Patienten im Allgemeinen mit der medizinischen Versorgung zufrieden waren. Die Durchschnittswerte in den Fragebögen EQ‐5D‐3L und EORTC QLQ C‐30 wiesen auf eine gute subjektive Allgemeingesundheit hin. Schlussfolgerungen Trotz der Toxizität, der Dauer und des Aufwands der Behandlung über ein Jahr entschied sich die Mehrzahl der Patienten für eine adjuvante Behandlung.

show abstract

“…26 In another analysis, the authors also highlighted that younger clinicians tend not to recommend additional sources of information and support in contrast to older clinicians, while non-recommending of decisionaids was irrespective of the clinicians' gender and qualification. 27 Hence, especially younger dermatooncologists should be encouraged to involve their patients in the decision-making processes about the disease or respective treatment. Besides, counseling with experienced dermato-oncologists about their preferred decision-aids might be a first step towards improved shared decisionmaking.…”

Section: General Impressionmentioning

confidence: 99%

Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey

Steeb

Wessely

Merkl

et al. 2021

PPA

Self Cite

View full text Add to dashboard Cite

Purpose: An important measure of hospital quality is the satisfaction of the patients receiving in-patient care. This cross-sectional study aimed to assess skin cancer patients' experiences in a university hospital setting as a measure of quality of cancer care. Patients and Methods: Questionnaires were mailed to patients with skin cancer after receiving in-patient overnight treatment in the dermatological unit of the university hospital Erlangen (Germany) from 1 September to 30 November 2017. Patients were asked to evaluate their overall experience of this episode of care and to complete the Picker Inpatient Survey questionnaire on specific aspects of their care, such as patient satisfaction regarding contact with staff, need for information, recommendation of the hospital as well as tumor-specific questions. The results were re-coded as problems and reported as frequencies and their percentage. Results: A total of 103 of 159 questionnaires were returned (64.8%). All patients rated the treatment and care they had received to be good or very good. Additionally, all patients would recommend our in-patient clinic to their families or friends. The patients most commonly criticized inconsistency of care delivered by the same physician (29.7%, 30/ 101) and feeling of insufficient involvement in the decision-making processes (21.1%, 20/ 95). Besides this, 19.0% (11/58) and 34.6% (18/52) of patients were not satisfied with physicians and nurses, respectively, appropriately addressing their fears or anxieties. In the cancer-specific questionnaire, the majority of patients were dissatisfied with further support regarding professional and social rehabilitation possibilities (85.7%, 30/35) and psychooncology (56.3%, 18/32). Conclusion: Overall, the majority of patients were satisfied with the in-patient skin cancer treatment. However, physicians and nurses can enhance patient satisfaction by addressing patients' fears and anxieties regarding their disease and treatment. Besides, our results highlight the importance of psycho-oncological support.

show abstract

Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences

Cited by 4 publications

References 5 publications

Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies

Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies

Therapieverständnis und gesundheitsbezogene Lebensqualität bei Patienten mit Melanom im Stadium III/IV unter Behandlung mit neuen adjuvanten Therapien

Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey

Contact Info

Product

Resources

About